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Abstract	  A	   novel	   and	   rapid	   (45	  min),	   quantitative	   chemiluminescence-­‐based,	   surface	  immunoassay	   is	   reported	   for	   the	   quantitative	   detection	   of	   progesterone	   and	  œstriol	  in	  artificial	  saliva.	  The	  detection	  limits	  for	  these	  pregnancy	  hormones	  are	  2.3	   and	   2.5	  pg	  mL-­‐1,	   respectively.	   	   The	   assay	   is	   based	   on	   the	   use	   of	   ferrocene-­‐tagged,	   monoclonal	   antibodies	   immobilised	   on	   a	   surface,	   so	   that	   the	   oxidised	  ferricenium	  catalyses	  the	  reaction	  between	  luminol	  and	  hydrogen	  peroxide.	  	  The	  immunoassay	   is	   performed	   in	   negative,	   such	   that	   increasing	   the	   antigen	  concentration	   gives	   rise	   to	   decreasing	   light	   intensity	   that	   is	   observed,	   and	   is	  unaffected	   by	   antibody	   orientation	   on	   the	   surface.	   	   This	   affords	   a	   method	   of	  calibration	   that	   is	   readily	   translated	   to	   pregnancy	   hormone	   detection	   in	   a	  primary	   point-­‐of-­‐care	   environment.	   	   Biomolecules	   with	   similar	   structures	   to	  these	   pregnancy	   hormones	   found	   in	   saliva	   are	   demonstrated	   not	   to	   interfere	  with	  the	  immunoassay.	  	  
Key	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Introduction	  Immunoassays	   are	   widely	   regarded	   as	   a	   technique	   to	   detect	   biochemical	  analytes	   that	   are	   present	   in	   trace	   amounts.1	   	   For	   “dipstick”	   sensing	   pathways,	  monoclonal	  antibodies	  are	  usually	   immobilised	  onto	  a	  solid	  surface.2	   	  Although	  documented	  procedures	  are	  available	  for	  the	  antibody	  immobilisation	  process,	  it	  is	   often	   challenging	   to	   undertake	   quantitative	   analysis	   at	   low	   antigen	  concentrations	  using	   such	  protocols,	   owing	   to	   the	   irreproducible	  nature	  of	   the	  surface	   modification.	   	   For	   example,	   the	   commonly	   deployed	   method	   of	  silanisation	   of	   a	   glass	   or	   plastic	   surface	   with	   (3-­‐aminopropyl)triethoxysilane	  followed	  by	  antibody	  immobilisation	  using	  a	  glutaraldehyde	  linker	  suffers	  from	  poor	   reproducibility,3-­‐5	   owing	   to	   batch-­‐to-­‐batch	   differences	   of	   glutaraldehyde	  and	  its	  self-­‐polymerisation.6	  	  Moreover,	  such	  surface-­‐confined	  immunoassays	  are	  affected	   by	   antibody	   orientation;	   	   the	   ideal	   scenario	   of	   the	   antigen	   binding	  fragment	  (Fab)	  region	  being	  readily	  accessible	  for	  interaction	  with	  the	  analyte.1	  	  	  	  In	   this	   work,	   we	   develop	   a	   protocol	   for	   quantitatively	   monitoring	   antigen	  concentrations	  at	  antibody-­‐modified	  surfaces,	  where	  antibody	  orientation	   is	  not	  an	   issue,7,8	   using	   the	   generation	   of	   chemiluminescence	   as	   the	   detection	   signal.	  	  Typically,	  chemiluminescence-­‐based	  immunoassay	  allows	  for	  a	  high	  sensitivities,	  with	   measurements	   of	   antigen	   concentration	   in	   the	   sub-­‐nanogramme	   per	  millilitre	   level	   possible,2	   with	   the	   reaction	   between	   luminol	   and	   hydrogen	  peroxide	   catalysed	   by	   horseradish	   peroxidase	   being	   most	   common.9	   	   In	   the	  latter,	  electron	  transfer	  catalysis	  through	  switching	  between	  FeIII	  and	  FeII	  redox	  states	  in	  the	  enzyme,10	  enables	  chemiluminescence.	  	  Since	  the	  active	  site	  within	  the	  enzyme	  is	  buried	  within	  the	  protein,	  the	  efficiency	  of	  the	  luminol/hydrogen	  peroxide	  reaction	  could	  be	  increased	  through	  the	  use	  of	  Fe3+,11	  ferricyanide,12	  or	  ferricenium	   ions	   molecular	   catalysts.13,14	   	   The	   latter	   species	   are	   readily	  electrochemically	  generated	   from	   ferrocene,	  which	   itself	   is	   a	   common	   label	   for	  electroimmunoassay.7	  	  	  	  Accordingly,	   in	   this	   work,	   we	   immobilise	   ferrocene-­‐labelled	   antibodies	   onto	   a	  transparent	   electrode	   surface,	   electrochemically	   oxidise	   the	   ferrocene-­‐tag	   and	  monitor	   chemiluminescence	   both	   in	   the	   absence,	   and	   presence,	   of	   various	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concentrations	   of	   antigen	   in	   artificial	   saliva.	   	   Saliva	   is	   considered	   to	   be	   an	  excellent	   medium	   for	   biomarker	   detection,15	   since	   clinical	   samples	   may	   be	  collected	  simply,	  safely	  and	  non-­‐invasively,	  without	   incurring	  discomfort	   to	  the	  patient.16	  	  In	  this	  work,	  the	  antigen	  is	  either	  progesterone	  or	  œstriol,	  as	  these	  are	  pregnancy	  biomarkers,	  for	  which	  monoclonal	  antibodies	  with	  high	  affinity	  have	  been	   developed.17	   	   Progesterone	   is	   involved	   in	   conception,	   so	   that	   low	  concentrations	   can	   give	   rise	   to	   early	   indications	   of	   potential	  miscarriage,	   pre-­‐term	   birth	   and	   the	   health	   of	   the	   developing	   fœtus;18,19	   	   œstriol	   likewise	   is	  important	   for	   fœtal	   development	   and	   the	   onset	   of	   labour.20	   	   Progesterone	  concentrations	   in	   saliva	   during	   pregnancy	   are	   reported	   as	   around	   7	  pg	  mL-­‐1	  (during	  the	  follicular	  phase),21	  140	  pg	  mL-­‐1	  (during	  the	  luteal	  phase),21	  and	  with	  an	   upper	   threshold	   of22	   500	  pg	  mL-­‐1.	   	   Furthermore,	   it	   has	   been	   reported	   that	  there	   is	   a	   significant	   correlation	   between	   saliva	   progesterone	   and	   serum	  progesterone	   during	   the	   menstrual	   cycle,23	   whilst	   a	   weak	   correlation	   exists	  during	  late	  preganancy.24	  	  For	  œstriol,	  the	  clinically	  relevant	  upper	  threshold	  is25	  5	  ng	  mL-­‐1.	   	  It	  has	  been	  found	  that	  strong	  correlations	  between	  blood	  serum	  and	  saliva	  levels	  exist	  during	  normal26,27	  and	  third	  trimester	  pregnancy.28	  	  Moreover,	  it	  has	  been	  demonstrated	   that	   the	   ratio	  of	  œstriol-­‐to-­‐progesterone	   in	   the	  body	  may	   enable	   clinical	   insight	   for	   the	   onset	   of	   labour.29	   	   It	   thus	   follows	   that,	   fast,	  easy-­‐to-­‐use,	   reliable	   and	   inexpensive	  methods	   for	   the	  quantitative	  detection	  of	  both	   these	   antigens	   empowers	   the	   development	   of	   point-­‐of-­‐care	   devices	   to	  monitor	  the	  state	  of	  pregnancy.	  	  	  We	  first	  develop	  and	  characterise	  a	  new	  concept	   imaging	   immunoassay,	  before	  examining	  its	  use	  for	  the	  detection	  of	  both	  progesterone	  and	  œstriol	  in	  artificial	  saliva.	  	  We	  have	  chosen	  not	  to	  study	  real	  saliva	  samples	  since	  we	  wish	  merely	  to	  demonstrate	   our	  method	   of	   immunoassay	   –	   a	   challenge	  with	   saliva	   compared	  with	  serum	  is	   that	   the	   target	  hormones	  are	  at	   lower	   levels,	   typically	  1%	  of	   the	  serum	   concentration.30	   	   Although	   our	  monitoring	   of	   free	  hormones	   in	   artifcical	  saliva	   overcomes	   problems	   associated	   with	   biologically	   inactive,	   protein-­‐conjugated	   hormones	   in	   blood	   serum,	   we	   ignore	   real	   matrix	   effects	   and	  interferences,	   such	   as	   endogenous	   peroxidases	   which	   could	   quench	   the	  chemiluminescent	  signal.	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2.	  	  Experimental	  	  
	  
2.1	  	  Chemical	  and	  Biochemical	  Reagents	  Mouse	  monoclonal	   anti-­‐progesterone	   [pg.	  53]:	   reactivity	   human	   (isotype	   IgG1,	  ab9187,	  1	  mg	  mL-­‐1),	  and	  rabbit	  monoclonal	  anti-­‐œstriol	   [EPPTXR3]	  (ab221960,	  1.01	  mg	  mL-­‐1)	   antibodies	   were	   purchased	   from	   Abcam.	   	   For	   the	   experiments	  reported	   in	   Figure	   5,	   the	   antibody	   used	   was	   mouse,	   monoclonal,	   anti-­‐cardiac	  troponin	  T	  antibody	  (ab8295,	  1	  mg	  mL-­‐1)	  purchased	  from	  Abcam.	  	  Progesterone,	  œstriol,	   testosterone,	   œstradiol,	   and	   œstrone	   were	   purchased	   from	   Sigma-­‐Aldrich	   in	   the	   purest	   grade	   commercially	   available,	   and	   used	   as	   received.	   	   4-­‐Nitrobenzene	   diazonium	   tetrafluoroborate	   (Fast	   Red	   GG	   salt),	  tetrabutylammonium	   perchlorate	   (TBAP),	   ferrocenecarboxaldehyde	   (FcCHO),	   ,	  sodium	  borohydride	  (NaBH4),	  Tween	  20	  and	  luminol	  were	  obtained	  from	  Sigma.	  	  	  Hydrogen	   peroxide	   (20	  vol,	   >6%	   w/v),	   hydrochloric	   acid,	   potassium	   chloride,	  sodium	   hydroxide,	   ethanol,	   acetonitrile,	   N,N-­‐dimethylformamide	   (DMF)	   and	  potassium	   carbonate	   were	   obtained	   from	   Fisher-­‐Scientific.	   	   Vitamin	   D3	   was	  purchased	   from	   Alfa	   Aesar.	   	   Water,	   with	   a	   resistivity	   of	   18.2	   MΩ	   cm,	   was	  obtained	   from	   an	   Elgastat	   system.	   	   Aqueous	   buffer	   solution	   was	   phosphate	  buffered	   saline	   (PBS)	   at	   pH	   7.4,	   prepared	   by	   dissolving	   one	   phosphate	   tablet	  (supplied	  from	  Sigma-­‐Aldrich)	  containing	  137	  mM	  NaCl,	  2.7	  mM	  KCl	  and	  10	  mM	  phosphate	   in	   200	  mL	   deionised	   water.	   N-­‐hydroxysulfosuccinimide	   (sulfo-­‐NHS,	  5	  mM,	   2.2	  mg)	   and	   N-­‐(3-­‐dimethylaminopropyl)-­‐N’-­‐ethylcarbodiimide	  hydrochloride	   (EDC,	  2	  mM,	   0.8	  mg)	   were	   purchased	   from	   Sigma-­‐Aldrich	   and	  both	   dissolved	   in	   10	   mM	   PBS	   (2	  mL)	   immediately	   prior	   to	   use.	   	   All	   other	  chemicals	  were	  purchased	  from	  Sigma-­‐Aldrich	  (UK)	  in	  the	  highest	  purity	  grade	  commercially	   available	   and	   used	   without	   further	   purification.	   	   Artificial	   saliva	  was	   prepared	   as	   described	   by	   West	   et	   al.31	   and	   consisted	   of	   deionised	   water	  containing	   NaCl	   (1.954	  g	  L-­‐1),	   NH4NO3	   (0.328	  g	  L-­‐1),	   KH2PO4	   (0.639	  g	  L-­‐1),	   KCl	  (0.202	  g	  L-­‐1),	  sodium	  salt	  of	  uric	  acid	  (0.021	  g	  L-­‐1),	  potassium	  citrate	  (0.308	  g	  L-­‐1),	  urea	  (0.198	  g	  L-­‐1),	  sodium	  salt	  of	  lactic	  acid	  (0.146	  g	  L-­‐1)	  and	  bovine	  submaxillary	  gland	  mucin	  Type	  I-­‐S	  (30	  g	  L-­‐1).	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2.2	  	  Instrumentation	  Electrochemical	   studies	   were	   performed	   in	   a	   modified	   three-­‐electrode	   set-­‐up	  with	  a	   tin-­‐doped	   indium	  oxide	   (ITO)	  coated	  glass	  working	  electrode	   (CB-­‐50IN-­‐CUV,	   sheet	   resistance	   5-­‐15	   Ω,	   dimensions	   7	  x	  50	  x	  0.7	  mm,	   Delta	   Technologies	  Ltd.,	  USA).	  A	  defined	  area	  was	  prepared	  with	  Fisherclark	  WS5002	  self	  adhesive	  paper	   reinforcement	   rings	   (determined	   using	   a	   travelling	  microscope	   to	   be	   of	  diameter	  6	  mm),	  with	  one	  end	  used	   for	   electrical	   connection	  via	   application	  of	  copper	  tape.	  	  Up	  to	  three	  individual	  electrode	  areas	  were	  prepared	  per	  electrode.	  	  	  	  Electrochemical	   measurements	   were	   made	   in	   a	   70	   µL	   sample	   droplet	   with	   a	  nickel	  wire	  counter	  electrode	  and	  a	  saturated	  calomel	  reference	  electrode	  (SCE,	  Hach).	   	  All	  potentials	  are	  reported	  here	  against	  this	  reference,	  unless	  otherwise	  stated.	   	   Measurements	   were	   controlled	   by	   a	   µ-­‐AUTOLAB-­‐type-­‐III	   or	   Autolab	  PGSTAT101	  potentiostat.	  	  	  Chemiluminescence	   analysis	   was	   undertaken	   using	   a	   QHY6	   charge	   coupled	  device	   camera	   (CCD,	   QHXCCD,	   USA)	   fitted	   with	   a	   high	   resolution	   pixel	   lens	  (8	  mm,	   Computar,	   USA),	   and	   recorded	   using	   EZCAP	  3.21	  software	   (QHXCCD,	  USA).	  	  Measurements	  were	  made	  within	  a	  dark	  box.	  	  Prior	  to	  measurement,	  the	  antibody-­‐modified	  surface	  was	  placed	  below	  the	  camera	  with	  a	   focussed	  image	  to	   record	   the	   background	   and	   subtract	   this	   from	   the	   experimental	   signal.	  	  Analysis	  of	   the	  resulting	  chemiluminescence	  photographs	  was	  performed	  using	  Image	   J	   software,	   where	   an	   average	   pixel	   intensity	   measurement	   was	   taken	  across	  the	  entire	  image.	  	  	  
	  All	  measurements	  were	  undertaken	  at	  ambient	  temperature	  (293	  ±	  2	  K).	  	  
2.3	  	  Synthesis	  of	  Ferrocene-­‐Labelled	  Antibodies	  Antibodies	  were	  chemically	  labelled	  with	  ferrocene	  through	  the	  coupling	  scheme	  reported	  previously:7,8,32	  	  10	  µL	  of	  neat	  antibody	  were	  diluted	  to	  200	  µL	  with	  10	  mM	  PBS	  (pH	  7.4)	  and	  the	  pH	  adjusted	  to	  pH~9	  by	  addition	  of	  5	  wt.%	  potassium	  carbonate,	   with	   subsequent	   dilution	   with	   a	   100	  mg	  mL-­‐1	   solution	   of	   ferrocene	  carboxaldehyde	  (FcCHO)	  in	  DMF	  (20	  mg	  in	  200	  µL),	  such	  that	  the	  FcCHO	  was	  in	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excess.	  This	  was	   followed	  by	   incubation	  at	   ambient	   temperature	   for	  30	  min	   to	  form	   the	   imine,	   and	   subsequently	   reduced	  with	   sodium	  borohydride	   (2.2	  mg),	  and	  incubated	  at	  ambient	  temperature	  for	  10	  min	  in	  order	  to	  form	  the	  secondary	  amine.	  	  The	  solution	  pH	  was	  adjusted	  to	  pH	  ~7	  using	  0.1	  M	  HCl.	  	  Excess	  tag	  and	  solvent	   were	   removed	   from	   the	   ferrocene-­‐conjugated	   antibody	   product	   after	  reaction	   by	   centrifugation	   and	  washed	  with	   10	  mM	   PBS	   (12	   krpm	   for	   20min,	  followed	  by	  twice	  washing	  with	  PBS	  at	  12	  krpm	  for	  5	  mins,	  using	  Vivaspin	  500	  centrifugal	  filters	  purchased	  from	  GE	  Healthcare,	  Sweden).	  Ultimately	  400	  µL	  of	  the	   purified	   and	   concentrated	   ferrocene-­‐conjugated	   antibody	   (at	   25	  µg	  mL-­‐1)	  was	  obtained	  and	  stored	  within	  a	  refrigerator	  at	  277	  K	  until	  immediately	  prior	  to	  use.	  	  
2.4	  	  ITO	  Surface	  Modification	  with	  Amine	  Groups	  	  ITO	   electrodes	   were	   cleaned	   prior	   to	   modification	   with	   isopropanol.	   Amine	  modification	   of	   the	   electrode	   surface	   was	   achieved	   through	   electrochemical	  reduction	  of	  2	  mM	  4-­‐nitrobenzene	  diazonium	  tetrafluoroborate	   in	  0.1	  M	  TBAP-­‐MeCN	   for	   the	   period	   of	   three	   reduction-­‐oxidation	   cycles	   (+0.7	   V	   to	   -­‐0.4	   V)	   at	  0.1	  V	  s-­‐1	  to	  yield	  a	  nitrobenzene	  modified	  electrode,	  followed	  by	  six-­‐electron,	  six-­‐proton	   reduction	   to	   afford	   the	   amine,	   aqueous	   ethanol	   containing	   0.1	   M	   KCl	  (90:10,	  v/v)	  from	  +0.4	  V	  to	  -­‐1.25	  V	  vs.	  SCE	  through	  three	  redox	  cycles	  at	  0.1	  V	  s-­‐1.	  	  
2.5	  	  Bio-­‐Conjugation	  of	  Ferrocene	  Labelled	  Antibodies	  to	  ITO	  Surface	  The	   immobilisation	  of	  antibody	  on	   the	  electrode	  surface	  was	  achieved	   through	  the	   coupling	   of	   carboxylic	   acid	   groups	   of	   the	   antibody	   to	   the	   primary	   amine	  groups	  of	  the	  phenylamine-­‐modified	  ITO	  electrode	  surface	  via	  an	  amide	  linkage,	  in	  a	  manner	  reported	  previously.7,8	  	  The	  400	  µL	  aliquot	  of	  ferrocene-­‐conjugated	  antibody	  was	  mixed	  with	  the	  same	  volume	  of	  activation	  buffer	  (2	  mM	  EDC	  and	  5	  mM	  sulfo-­‐NHS	  in	  10	  mM	  PBS)	  for	  15	  min	  to	  activate	  the	  carboxy	  terminal	  of	  the	  antibody.	   Subsequently,	   30	   µL	   of	   this	   solution	   was	   applied	   to	   the	   amine	  functionalized	   ITO	  electrode	  and	  stored	  at	  277	  K	   for	  18	  hours,	   after	  which	   the	  electrodes	  were	  washed	  with	  0.1	  vol.%	  Tween	  20	  in	  10	  mM	  PBS,	  followed	  by	  PBS	  to	   remove	   unbound	   antibody,	   before	   drying	   under	   N2	   stream.	   The	   electrodes	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were	   used	   immediately,	   or	   stored	   in	   10	  mM	   PBS	   at	   277	   K	   until	   use.	   	   Typical	  storage	  times	  ranged	  from	  24-­‐48	  h.	  
	  
2.6	  	  Hormone	  Measurement	  First,	  any	  non-­‐specific	  binding	  sites	  on	  the	  modified	  ITO	  surface	  were	  blocked	  by	  the	   addition	   of	   20	   µL	   of	   1	   wt.	  %	   BSA-­‐10mM	   PBS,	   pH	   7.0	   for	   30	  min	   at	   room	  temperature.	  	  Following	  this,	  the	  modified	  electrodes	  were	  rinsed	  with	  0.1	  vol.%	  Tween	  20	  in	  10	  mM	  PBS	  followed	  by	  PBS.	  	  All	  electrodes	  were	  then	  conditioned	  in	  a	  70	  µL	  PBS	  droplet	  using	  cyclic	  voltammetry	  at	  0.1	  V	  s-­‐1	  for	  three	  consecutive	  scans	   in	   the	   range	   -­‐0.05	  -­‐	  +0.6	  V	  vs.	  SCE.	   	   The	   ferrocene	   tags	   were	   then	  electrochemically	   oxidised	   using	   a	   0.01	  V	  s-­‐1	   scan	   rate,	   sweeping	   in	   the	   same	  range,	   but	   stopping	   after	   the	   oxidation	   wave,	   to	   afford	   the	   oxidised	   tag	  (ferricenium).	  	  Chemiluminescence	  measurements	   were	   undertaken	   through	   first	   recording	   a	  background	   image,	   and	   then	   adding	   a	   70	  mL	   PBS	   droplet	   containing	   10	  mM	  luminol,	   10	  mM	   hydrogen	   peroxide	   and	   0.1	  M	   NaOH	   to	   the	   surface,	   and	   then	  recording	  an	  image.	  	  After	  this,	  the	  antibody-­‐modified	  electrodes	  were	  incubated	  in	   known	   30	  µL	   of	   known	   concentrations	   of	   antigen	   in	   either	   10	   mM	   PBS	   or	  artificial	   saliva	   for	   particular	   time	   periods	   (15,	   30	   and	   60	  min)	   at	   room	  temperature	  (50-­‐60%	  relative	  humidity).	   	  After	  incubation,	  the	  electrodes	  were	  rinsed	   with	   Tween	   20	   and	   PBS,	   followed	   by	   drying	   in	   a	   nitrogen	   stream,	   to	  remove	   any	   loosely	   bound	   antigen.	   	   The	   electrodes	  were	   then	   subject	   to	   a	   re-­‐examination	   of	   the	   chemiluminescence	   measurement	   in	   PBS.	   	   Interference	  studies	   in	   artificial	   saliva	  were	   undertaken	   using	   20	  ng	  mL-­‐1	   of	   the	   interfering	  species,	  and	  incubated	  for	  30	  min,	  all	  other	  protocols	  remaining	  the	  same.	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3.	  	  Results	  and	  Discussion	  We	  first	  characterise	  the	  ferrocene-­‐tagged	  antibodies	  in	  terms	  of	  the	  number	  of	  ferrocene	  moieties	  sprinkled	  over	   the	  antibody	  surface	  and	  the	  surface	  density	  of	  antibodies	  immobilised	  on	  the	  electrode	  surface,	  before	  examining	  the	  use	  of	  these	  for	  catalysing	  the	  reaction	  between	  luminol	  and	  hydrogen	  peroxide.	  	  
3.1	  	  Characteristisation	  of	  Ferrocene-­‐Tagged	  Antibodies	  The	   characterisation	   of	   ferrocene-­‐conjugated	   anti-­‐progesterone	   antibodies	   in	  PBS	  by	  UV-­‐visible	   spectrophotometry	   revealed	  peak	  absorbances	   in	   the	   region	  300-­‐350	  nm	  and	  at	  454	  nm	  (q.v.	  Figure	  1a).	  	  As	  expected	  from	  the	  Lambert-­‐Beer	  law,	  these	  were	  directly	  proportional	  to	  antibody	  concentration	  at	  low	  antibody	  concentration,	   affording	   an	   extinction	   coefficient	   of	   16.7	  mL	  mg-­‐1	  cm-­‐1	   (Figure	  1b).	  	  	  	  
	  





Figure 4.6: UV-Visible spectra of a) ferrocenecarboxaldehyde and b) the ferrocene tagged anti-
progesterone antibodies. 
 
It can be seen from spectrum 4.6a there was an absorbance peak at 460 nm and two 
shoulder peaks at 310 and 350 nm, the peak observed at 460 nm is in agreement with the 
literature where values of between 440 and 460 nm hav  been quoted for 
ferrocenecarboxaldehyde.188, 189 The shoulder peaks observed in the UV region of the 
spectra are weak and from previous work this is expected, and was due to the 
cyclopentadienyl rings from the ferrocene. Figure 4.6b shows the UV-Vis spectra of the 
ferrocene tagged anti-progesterone with peaks at 440 nm and at 320 nm and a third sharp 
peak at 250 nm. The peaks at 440 and 320 nm are due to the ferrocene moieties and with 
the sharp peak at 250 nm due to protein absorption which is typically observed between 





By carrying out this investigation the success of the antibody tagging was determined. 
Comparing figure 4.6a and 4.6b there was a slight shift in the peaks observed based on 
the ferrocene moieties which can be an attribute of the conjugation of the ferrocene to the 
antibody.191 Using Beer-Lambert Law a calibration of the ferrocene-tagged anti-
progesterone and the ferrocenecarboxaldehyde was created. Through taking the ratio of 
the extinction coefficients of the two systems the average number of tags could be 
estimated.192 This assumed all the ferrocene present was tagged to the antibodies, with 
none present in solution. 
 
 
Figure 4.7: Calibration curves of a) ferrocenecarboxaldehyde and b) ferrocene tagged anti-
progesterone, with absorption values taken at 454 nm. 
b) 
a) 
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We	   have	   demonstrated	   that	   voltammetric	   interrogation	   ferrocene-­‐tagged	  antibodies	   immobilized	   through	   the	  platform	  developed	  on	   ITO	   electrodes	   can	  be	  treated	  as	  essentially	  electrochemically	  reversible	  at	  low	  scan	  rates.7,8	  	  Figure	  2	  illustrates	  a	  linear	  sweep	  voltammogram	  of	  the	  immobilized	  ferrocene-­‐labelled	  antibodies	   at	   a	   scan	   rate	   of	   10	   mV	  s-­‐1,	   after	   cyclic	   voltammetric	   conditioning	  using	  three	  consecutive	  cycles	  at	  100	  mV	  s-­‐1.	  	  	  	  
	  
Figure	  2:	  	  Linear	  sweep	  voltammogram	  (at	  0.01	  V	  s-­‐1)	  corresponding	  to	  the	  oxidation	  of	  ferrocene-­‐labelled	  anti-­‐progesterone	  antibodies	  immobilised	  on	  an	  ITO	  electrode.	  	  The	   broad	   but	   well-­‐defined	   voltammetric	   wave	   with	   peak	   potential	   of	  +0.25	  V	  vs.	  SCE	   is	   indicative	   of	   oxidation	   of	   the	   ferrocene	   labels	   (Fc)	   to	  ferricenium	  (Fc+):	  
	   	   	   	   	   	   	   	   (1)	  Assuming	  all	   ferrocene	  tags	  contribute	  to	  the	  wave,	   the	  charge	  under	  the	  wave	  (1.04	  µC),	   together	  with	  the	  estimate	  of	   ferrocene	  tags	  per	  antibody,	  affords	  an	  antibody	  density	  on	  the	  electrode	  of	  ca.	  2.9	  x	  10-­‐12	  mol	  cm-­‐2.	   	  Further,	  under	  the	  assumption	   of	   close-­‐packing	   of	   monolayer	   antibodies	   on	   the	   nanostructured	  surface,	   these	   results	   afford	   an	   antibody	   diameter	   of	   around	   8.5	  nm,	   which	   is	  approximately	   in	   agreement	   with	   the	   reported	   size	   of	   typical	   monoclonal	   IgG	  antibodies.33	   	   Taken	   together,	   this	   suggests	   that	   the	   primary	   source	   of	  discrepancy	   in	   the	  number	  of	   ferrocene	  moieties	  per	  antibody	  to	  be	  due	  to	   the	  different	  number	  of	  primary	  amine	  functional	  groups	  in	  both	  proteins.	  	  We	  next	   investigate	   the	  ability	  of	   the	   ferricenium-­‐based	  surface	   to	  catalyse	   the	  
Fc − e− ⎯→⎯←⎯⎯ Fc+
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chemiluminescence	  between	  luminol	  and	  hydrogen	  peroxide.	  	  
3.2	  	  Surface-­‐Based	  Chemiluminescence	  for	  Immunoassay	  The	   electrochemical	   oxidation	   of	   the	   immobilised	   ferrocene-­‐conjugated	  antibodies	   depicted	   in	   Figure	   2	   enables	   the	   electrochemical	   generation	   of	   a	  surface-­‐confined	   FeIII	   catalyst	   for	   the	   luminol/H2O2	   chemiluminescent	  reaction.34-­‐38	   	   Figure	   3,	   panel	   (a)	   illustrates	   typical	   results	   of	   the	  electrochemically	  oxidised	  surface	  in	  the	  presence	  of	  an	  equimolar	  luminol/H2O2	  alkaline	   solution	   after	   200	  s,	   where	   it	   is	   readily	   seen	   that	   the	   large	   surface	  density	  of	  antibodies	  and	  the	  high	  number	  of	   ferrocene	  tags	  enable	  an	  efficient	  and	  almost	  uniform	  generation	  of	  light	  over	  the	  disc	  surface.	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  3:	  	  Chemiluminescence	  images	  (exposure	  time	  200	  s)	  at	  ferricenium-­‐labelled	  anti-­‐progesterone	  antibodies	  immobilised	  on	  an	  ITO	  electrode	  surface	  immersed	  in	  10	  mM	  hydrogen	  peroxide,	  10	  mM	  luminol	  and	  0.1	  M	  aqueous	  sodium	  hydroxide	  (a,	  left)	  immediately	  prior	  to,	  and	  (b,	  right)	  after	  60	  min	  incubation	  with	  10	  ng	  mL-­‐1	  of	  progesterone	  in	  PBS.	  	  Following	   Schiffrin	   and	   Wilson,13,14	   we	   propose	   that	   the	   electrochemically	  oxidised	  form	  of	  the	  redox	  tag	  (ferricenium)	  acts	  as	  the	  heterogeneous	  catalyst	  for	  the	  chemiluminescent	  reaction	  between	  hydrogen	  peroxide	  and	  luminol	  (see	  ESI	  1	  for	  the	  proposed	  reaction	  mechanism).	   	  The	  oxidised	  form	  of	  ferrocene	  is	  unstable	  through	  reaction	  with	  both	  oxygen39	  and	  chloride.40	  	  Thus,	  incubation	  of	  the	   surface	   in	   aqueous	   aerobic	   solutions	   can	   lead	   to	   a	   decrease	   in	   the	  performance	  of	  the	  catalyst	  at	  short	  periods	  of	  time.	  	  Evidence	  for	  this	  is	  given	  in	  Figures	   4	   and	   5,	   where	   it	   is	   seen	   that	   increasing	   the	   storage	   time	   of	   the	  ferricenium	   species	   in	   PBS,	   or	   other	   aqueous	   electrolytes,	   leads	   to	   a	   first	   to	  decrease	   in	  the	  observed	  chemiluminescence,	  and,	  after	  two	  days	   incubation	  in	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chloride	   electrolytes,	   actually	   leads	   to	   an	   large	   increase	   in	   the	   observed	  chemiluminescence	   intensity.	   	   These	   results	   are	   explained	   by	   the	   catalyst	  (ferricenium)	   breaking	   down	   in	   the	   presence	   of	   chloride	   to	   FeCl4-­‐,	   which	   is	  considered	   to	   be	   a	   more	   efficient	   catalyst	   for	   the	   reaction	   between	   hydrogen	  peroxide	  and	  luminol.	  	  The	  breakdown	  of	  the	  catalyst	  in	  saliva	  is	  less	  of	  an	  issue	  compared	   with	   PBS,	   as	   the	   chloride	   concentration	   is	   in	   the	   former	   (typically	  ~30	  mM)31	  is	  between	  four	  and	  five	  times	  smaller	  than	  in	  PBS	  (140	  mM).	  
	  




        
 
       
Figure 5.4: CL images of ferrocene-tagged anti-progesterone, where a) represents the ferrocene 
molecule before oxidation, b) immediately after ferrocene oxidation, c) 1 hour after ferrocene 
oxidation and d) 1 day after oxidation 10 mM luminol (pH 9) and 10 mM H2O2. 
 
For a system that will be used for POC the system needs to be simple with minimal 
reaction steps, therefore a system where ferrocene oxidation is needed before every CL 
measurement would not be favourable, thankfully as shown in figure 5.3 where no 
oxidation has occurred no signal was seen this confirms that ferrocene in its neutral state 
does not catalyse the hydrogen peroxide/luminol reaction 5.4a, 5.4b after oxidation the 
light signal increases showing that in the oxidised state the catalysis occurs with 5.4c 
showing the oxidised ferrocene after one hour storage in PBS and 5.4d after one day 
storage in PBS. Showing the system is stable and therefore can be utilised as a route to 
carry out a CL immunoassay that can be incorporated into a POC system. It has been 
reported that ferrocene can be stable in aqueous solutions.213 This stability in large could 
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Figure	  5:	  	  Effect	  of	  incubation	  time	  (without	  antigen)	  in	  aqueous	  aerobic	  electrolytes	  on	  the	  observed	  chemiluminesce	  of	  ferricenium-­‐tagged	  antibodies	  immobilised	  on	  an	  ITO	  surface.	  	  The	  data	  reported	  are	  the	  absolute	  chemiluminescent	  intensity	  average	  of	  three	  spots	  (assed	  from	  images	  acquired	  using	  a	  200	  s	  exposure	  time	  using	  luminol	  and	  hydrogen	  peroxide	  concentrations	  of	  10	  mM),	  with	  the	  error	  bars	  representing	  one	  standard	  deviation.	  	  Key:	  	  water	  (red	  circles),	  10	  mM	  PBS	  (blue	  squares),	  10	  mM	  NaHCO3	  (green	  triangles),	  1.0	  M	  KCl	  (black	  diamonds).	  	  Lines	  showing	  trends	  are	  included	  merely	  to	  guide	  the	  eye.	  	  Optimisation	  studies	  (see	  ESI	  2)	  identified	  the	  following	  conditions	  for	  maximum	  chemiluminsecent	  signal:	  	  200	  s	  CCD	  exposure	  time	  and	  equal	  concentrations	  of	  luminol	   and	   hydrogen	   peroxide	   at	   10	  mM.	   	   	   Accordingly,	   all	   subsequent	  experiments	  were	  undertaken	  under	  these	  conditions.	  	  It	   follows	   that	   since	   the	   chemiluminescence	   intensity	   is	   proportional	   to	   the	  surface	  coverage	  of	  catalyst,	  and	  because	   the	   ferrocene	  tags	  are	  predominantly	  located	   on	   the	   antibody	   paratopes,7,8	   the	   blocking	   of	   the	   ferricenium	  moieties	  from	  the	  aqueous	  solution	   through	  antibody	  complexation	  with	  antigen	  should	  reduce	  the	  surface	  density	  of	  the	  chemiluminescence	  catalyst,	  resulting	  in	  lower	  amounts	  of	  chemically	  generated	   light.	   	  This	   is	  observed	   in	  Figure	  3,	  panel	   (b):	  	  incubation	   for	  60	  min	  with	  10	  ng	  mL-­‐1	   antigen	  causes	  a	  major	   reduction	   in	   the	  light	   generated	   across	   the	   entire	   antibody-­‐modified	   surface.	   	   Accordingly,	   we	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report	  the	  extent	  of	  antigen	  binding	  to	  the	  antibody-­‐modified	  surface	  (θ)	  through	  the	   ratio	   of	   the	   overall	   light	   intensities	   (S),	   in	   a	   manner	   tantamount	   to	   the	  “taring”	  of	  a	  balance:	  
	   	   	   	   	   	   	   	   (2)	  In	   equation	   (2),	   0	  ≤	  θ	  ≤	  1	   and	   (S)antigen	   refers	   to	   the	   overall	   light	   intensity	   after	  antigen	  incubation,	  whilst	  (S)no	  antigen	  is	  that	  observed	  immediately	  before	  antigen	  incubation.	  	  	  Thus,	  the	  variation	  of	  the	  light	  intensity	  with	  antigen	  concentration	  affords	  an	  exquisite	   route	   to	   immunoassay	   in	  negative:	   	  higher	   light	   intensities	  are	  expected	  for	  lower	  antigen	  concentrations.	  	  We	  next	  describe	  the	  use	  of	  this	  sensing	  protocol	  for	  immunoassay.	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immunoassay	   enables	  discrimination	  of	   antigen	   concentration	  over	   five	   orders	  of	  magnitude,	  q.v.	  Figure	  6,	  panel	  c,	  with	  linear	  ranges	  of	  the	  analytical	  signal	  at	  60	  min	   incubation	   times	   for	   progesterone	   over	   the	   range	   0.1	  –	  100	  ng	  mL-­‐1	  (Pearson’s	   product-­‐moment	   correlation	   coefficient	   of	   0.9273),	   and	   for	   œstriol	  over	   the	   range	   0.01	  –	  100	  ng	  mL-­‐1	   (Pearson’s	   product-­‐moment	   correlation	  coefficient	   of	   0.9854),	   encouraging	   this	   methodology	   for	   pregnancy	   hormone	  detection.	  	  Matrix	  effects	  do	  not	  appear	  to	  be	  apparent.	  	  
Figure	  6:	  	  Time-­‐dependent	  antigen-­‐binding	  curves	  extracted	  from	  chemiluminescence	  images	  (10	  mM	  luminol,	  10	  mM	  H2O2	  and	  0.1	  M	  aqueous	  NaOH,	  exposure	  time	  of	  200	  s,	  over	  five	  repeats)	  with	  antigen	  incubation	  in	  PBS	  (a,	  top)	  and	  artificial	  saliva	  (b,	  middle),	  reanalysed	  to	  afford	  antigen	  calibration	  curves	  in	  artificial	  saliva	  (c,	  bottom),	  for	  antigen	  concentrations	  in	  the	  range	  0.01	  ≤	  [antigen]/ng	  mL-­‐1	  ≤	  100.0,	  at	  ferricenium-­‐labelled	  anti-­‐progesterone	  (i,	  left),	  or	  anti-­‐œstriol	  (ii,	  right)	  antibody	  modified	  ITO	  surfaces.	  	  In	  (a)	  and	  (b),	  the	  solid	  lines	  merely	  serve	  to	  guide	  the	  eye	  through	  the	  data	  points.	  	  The	  error	  bars	  represent	  one	  standard	  deviation.	  	  	  
	   16	  
Based	   on	   the	   data	   in	   Figure	   6,	   the	   quantifiable	   detection	   limits	   (at	   30	  min	  incubation	   time)	  are	  0.1	  ng	  mL-­‐1	   for	  both	  progesterone	  and	  œstriol	   in	  PBS,	  and	  0.01	  ng	  mL-­‐1	  for	  both	  antigens	  in	  artificial	  saliva.	  	  From	  the	  data	  in	  Figure	  6c,	  the	  limits	   of	   detection	   of	   both	   hormones	   in	   artificial	   saliva	   are	   calculated	   to	   be	  2.4	  pg	  mL-­‐1	   (progesterone)	   and	   2.5	  pg	  mL-­‐1	   (œstriol),	   based	   on	   3sb	   +	   average	  background	   signal,41	   which	   augers	   well	   for	   using	   this	   method	   for	   clinically	  relevant	  samples.	  	  	  In	  order	  to	  determine	  the	  extent	  of	  salivary	  interferences	  with	  similar	  structures	  to	   progesterone	   (testosterone	   and	   vitamin	   D3)	   and	   œstriol	   (œstradiol	   and	  œstrone),	   tests	   were	   undertaken	   to	   quantify	   the	   response	   of	   the	   antibody-­‐modified	  electrode.	  	  In	  these	  tests,	  20	  ng	  mL-­‐1	  of	  the	  potential	  interfering	  species	  (concentrations	  that	  are	  substantially	  larger	  than	  present	  in	  clinical	  context42,43)	  were	  incubated	  in	  PBS	  for	  30	  min,	  followed	  by	  washing	  and	  immunoassay.	  	  The	  results	  are	  reported	  in	  Figure	  7,	  where	  it	   is	  seen	  that	  for	  the	  anti-­‐progesterone	  modified	   electrode,	   structurally	   similar	   molecules	   exhibit	   coverages	   that	   are	  around	   seven	   times	   smaller	   than	   that	   for	   progesterone,	   whilst	   structurally	  similar	  molecules	  to	  œstriol	  give	  rise	  to	  coverages	  at	  the	  anti-­‐	  œstriol	  modified	  electrode	  that	  are	  about	  five	  times	  smaller	  than	  œstriol.	  	  	  
Figure	  7:	  	  Interference	  studies	  of	  the	  visual	  immunoassay,	  using	  20	  ng	  mL-­‐1	  antigen	  concentration	  in	  PBS	  incubated	  for	  30	  min	  on	  the	  ferricenium-­‐tagged	  antibody-­‐modified	  surface	  (anti-­‐progesterone	  antibody,	  a,	  left,	  or	  anti-­‐œstriol	  antibody,	  b,	  right),	  followed	  by	  imaging	  observation	  of	  chemiluminescence	  using	  an	  200	  s	  exposure	  time	  with	  10	  mM	  luminol,	  10	  mM	  H2O2	  and	  0.1	  M	  aqueous	  NaOH,	  and	  using	  equation	  (2)	  to	  determine	  blocking	  fractions.	  	  The	  error	  bars	  represent	  one	  standard	  deviation	  over	  three	  repeats.	  	  Clearly,	   this	   system	   exhibits	   a	   marked	   selectivity	   for	   the	   target	   antigen,	   as	  expected	   for	   monoclonal	   antibodies,	   even	   though	   the	   antigens	   are	   small	  molecules.44	   	   The	   data	   in	   Figure	   7	   were	   analysed	   in	   terms	   of	   a	   recovery	   test,	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using	   the	   data	   from	   Figure	   6	   (in	   PBS)	   as	   a	   crude,	   semi-­‐logarithmic	   calibration	  curve.	  	  A	  20	  ng	  mL-­‐1	  spiked	  sample	  (Figure	  7)	  afforded	  between	  10-­‐13	  ng	  mL-­‐1	  of	  progesterone	  or	  œstriol,	  yielding	  approximately	  50%	  recovery.	   	  Whilst	  this	   is	  a	  low	   recovery,	   this	   calibration	   is	   not	   optimised:	   	   the	   spiked	   sample	   contained	  potential	  interferences	  and	  the	  calibration	  curve	  from	  the	  data	  in	  Figure	  6	  could	  only	  be	  drawn	  to	  10	  ng	  mL-­‐1.	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4.	  	  Conclusions	  A	   novel	   and	   simple	   immunoassay	   has	   been	   developed	   employing	   surface-­‐catalysed	   luminol/hydrogen	   peroxide	   chemiluminescence,	   using	   ferrocene-­‐conjugated	   monoclonal	   antibodies,	   with	   the	   redox	   label	   in	   the	   oxidised	   state	  (ferricenium).	   	   In	   a	  manner	  equivalent	   to	  negative	   imaging	   in	   art,	   this	   imaging	  immunoassay	   gives	   rise	   to	   chemiluminescence	   intensities	   that	   decrease	   with	  increasing	   antigen	   concentration.	   	   The	   immunoassay	   demonstrates	   good	  reproducibility,	   and	   provides	   quantitative	   analysis	   in	   artificial	   saliva	   within	   a	  total	   analysis	   time	   of	   less	   than	   45	  min	   (from	   saliva	   sample	   acquisition	   to	   final	  result	  analysis)	   for	  both	  progesterone	  and	  œstriol.	   	  The	   inexpensive	  method	  of	  measurement,	   together	  with	   the	  non-­‐invasive	  nature	  of	   saliva,	   and	   the	  marked	  selectivity	   for	   the	   target	   antigen,	   encourages	   the	   exploitation	   of	   this	   sensing	  protocol	  within	  biosensors	  in	  a	  point-­‐of-­‐contact	  setting,	  for	  example,	  to	  monitor	  female	   sub-­‐fertility,	   since	   it	   reduces	   the	   risk	   of	   false	   positives	   from	   typical	  interferences	  in	  saliva.	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